Enzymotec is its ninth acquisition in 2017, and it's 28th in the last three years. Enzymotec is a specialty chemicals company that creates dietary supplements and medical food products from the lipids contained in fish and plants. One of the company's key products is the infant formula InFat, which mimics the composition, structure and nutritional value of the fat found in human breastmilk. It is sold through a joint venture between Enzymotec and Swedish manufacturer AAK. Frutarom has no significant activity in the infant formula area, which was one of the reasons Frutarom was interested in acquiring Enzymotec. Enzymotec subsidiary VAYA Pharma develops medical foods for the management of a number of medical conditions and diseases including ADHD for children and early memory impairment. Enzymoetic has 235 employees, mainly in Midgal HaEmek and the United States, and had sales in the last 12 months of $36.5 million.